-
Subject Areas on Research
-
A Novel Mycovirus Evokes Transcriptional Rewiring in the Fungus Malassezia and Stimulates Beta Interferon Production in Macrophages.
-
A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection.
-
A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study.
-
A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
-
ADAP2 Is an Interferon Stimulated Gene That Restricts RNA Virus Entry.
-
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
-
An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage.
-
Cloned endothelium derived from autoimmune vascular disease retain structural and functional characteristics of normal endothelial cells.
-
Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study.
-
Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals.
-
Cytokine expression by models of human trophoblast as assessed by a semiquantitative reverse transcription-polymerase chain reaction technique.
-
Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta.
-
Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts.
-
Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
-
Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling.
-
Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
-
Emerging Roles of Type-I Interferons in Neuroinflammation, Neurological Diseases, and Long-Haul COVID.
-
Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
-
Exosome-Mediated Delivery of Inducible miR-423-5p Enhances Resistance of MRC-5 Cells to Rabies Virus Infection.
-
GW112, a novel antiapoptotic protein that promotes tumor growth.
-
Gonococcal lipooligosaccharide suppresses HIV infection in human primary macrophages through induction of innate immunity.
-
IFN-beta inhibits human Th17 cell differentiation.
-
IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.
-
IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors.
-
Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling.
-
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
-
Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
-
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
-
Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.
-
Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma.
-
Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.
-
Interferon in the treatment of cutaneous T-cell lymphoma.
-
Interferon lambda protects the female reproductive tract against Zika virus infection.
-
Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele.
-
Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome.
-
Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS.
-
Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment.
-
Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.
-
Oncolytic virus-derived type I interferon restricts CAR T cell therapy.
-
Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter.
-
Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate.
-
Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages.
-
Post-transcriptional regulation of antiviral gene expression by N6-methyladenosine.
-
Regulation of microglial function by interferons.
-
Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity.
-
Sphingosine-1-phosphate inhibits IL-1-induced expression of C-C motif ligand 5 via c-Fos-dependent suppression of IFN-β amplification loop.
-
The IFN-inducible GTPase LRG47 (Irgm1) negatively regulates TLR4-triggered proinflammatory cytokine production and prevents endotoxemia.
-
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.
-
The induction of HMGB1 release from RAW 264.7 cells by transfected DNA.
-
The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis.
-
The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes.
-
The small GTPase RAB1B promotes antiviral innate immunity by interacting with TNF receptor-associated factor 3 (TRAF3).
-
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
-
Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
-
Type I interferon pathway in adult and juvenile dermatomyositis.
-
Update: biomarkers for idiopathic inflammatory myopathies.
-
Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus.
-
[NLRP3 inflammasome and multiple sclerosis/EAE].
-
Keywords of People